PET/CT Accurately Localizes Recurrent Prostate Cancer

Share this content:
Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.
Salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.
The following article features coverage from the American Society of Clinical Oncology (ASCO) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Imaging with 68Ga-PSMA11 PET/CT is highly accurate in localizing recurrent prostate cancer (PCa), according to data that presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, on Monday, June 4.1 In addition, salvage therapy guided by 68Ga-PSMA11 PET/CT resulted in high biochemical response rates.

In a phase 2/3 prospective trial ( Identifer: NCT02940262) conducted by Wolfgang Fendler, MD, and colleagues at the David Geffen School of Medicine at the University of Califnoria, Los Angeles, patients who experienced biochemical recurrence following radical prostatectomy (205 patients) or radiation therapy (45 patients) for PCa underwent 68Ga-PSMA11 PET/CT. Lesions were validated in 51% of PET/CT-positive patients by histopathology (33 patients), imaging (62 patients), and/or PSA after targeted radiation therapy (9 patients). PSA response following 68Ga-PSMA11 PET/CT guided focal salvage therapy (surgery/radiotherapy) was recorded for 23 of 25 patients.

The positive predictive value (PPV) by histopathology was 85% on a patient base (primary endpoint). PPV as determined by any type of validation was 89% on a patient base and 91% on a region base. 68Ga-PSMA11 PET/CT localized recurrent PCa in 197 (79%) of 250 patients. The rate varied by PSA (in ng/mL): 41% for PSA below 0.5; 66% for 0.5 to less than 1.0; 86% for 1.0 to less than 2.0; 96% for 2.0 to less than 5.0; and 99% for 5.0 ng/mL or higher.

68Ga-PSMA11 PET/CT localized 35% of lesions in the prostate bed, 61% in the pelvis, 35% outside the pelvis, and 31% in bone.

Following salvage therapy alone guided by 68Ga-PSMA11 PET/CT, 18 patients (78%) had a PSA drop of 50% of more and 7 (30%) had a complete biochemical response (PSA undetectable).

Read more of Cancer Therapy Advisor's coverage of the American Society of Clinical Oncology (ASCO) 2018 meeting by visiting the conference page.


  1. Fendler W, Calais J, Gartmann J, et al. Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. J Clin Oncol. 2018: 36, (suppl; abstr 5001). Presented at 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs